Furthermore, the positivity rates of IGF2BP3 in stage I, II, and III breast cancer were 15.1% (13/86), 13.2% (20/151), and 1.6% (1/62) respectively, with a statistically significant difference between groups (P=0.023). Here, IGF2BP3 is linked to breast carcinoma.